Webinar: Leveraging New Data Sets: How to Improve Prospecting, Investing, and Data-Driven Decisions in Biotech by InsideScientific

Leveraging New Data Sets: How to Improve Prospecting, Investing, and Data-Driven Decisions in Biotech

About

Join Matthew Gibbs and Ben Bau from BYTE51 and BioPharmCatalyst’s John Gagliano for a detailed discussion on why clinical data matters for investing, effective prospecting and client acquisition in biotech.

Access to current data is critical to make timely and well-informed investment decisions, identify promising prospects, and evaluate acquisition targets. However, access to catalyst and clinical trial data can be challenging, particularly for privately held entities. In this webinar, we will discuss tools to access and utilize new public and private datasets to make informed and, most importantly, data-driven decisions. Through merging of financial and clinical data, these tools provide a detailed and comprehensive picture, invaluable during periods of uncertainty and volatility.

Key Topics:

A detailed discussion on why clinical data matters for investing, effective prospecting and client acquisition.

A live demo of the BYTE51 data platform, showcasing real-time prospect identification and highlighting companies working on innovations like CAR-T cell therapy and Antibody Drug Conjugates.

Presenters

John Gagliano

Senior Director of BioPharmCatalyst

John serves as the Director of BioPharmCatalyst where he is responsible for project management and business strategy, as well as overseeing day-to-day operations. Prior to joining the BioPharmCatalyst team in April of 2021, John spent 10 years working within financial services across some of the major institutions in the industry, including Blackrock, J.P. Morgan, and Fidelity, where he mainly focused on business development and client engagement. John double majored in Finance and Spanish and received his degrees from Saint Joseph’s University.

Matthew Gibbs

Co-Founder/CEO, BYTE51

As the co-founder/CEO of BYTE51, I lead a life science data company that provides subscription access to $650B of VC funding and clinical data. Our platform empowers life science founders to raise capital, investors to source investments, and companies to prospect to grow their business. With over 18 years of experience in venture capital firm Oxford Bioscience Partners, we invested in 120 companies across five funds ($1.1B AUM), including notable deals like Human Genome Sciences (acquired by GSK for $3.6B), Illumina (ILMN $23B), Dicerna (acquired by NVO $3.3B) and Exelixis (EXEL $10B). I was also founding CEO of CipherBio, a SaaS product that aggregates $1.6 trillion of VC funding data for paid subscribers which raised $12.5M in capital. My mission is to leverage data to drive innovation and growth in the life science industry.

Ben Bau

Co-Founder/CTO, BYTE51

Ben is the co-founder/CTO of BYTE51. He has almost 20 years of experience leading technology development in healthcare and data. At Vecna Technologies, Ben led the development of software for the launch of the Massachusetts Health Connector and oversaw the Patient Check-in Kiosk product line, which was implemented across the Veterans Health Administration, within the Department of Defense, and across various commercial health systems. Subsequently, at RedBand Systems, Ben has led numerous software engagements providing software and data solutions to companies including Philips, Merck, GSK, and CipherBio as well as a range of startups and other businesses. He holds a degree in electrical engineering and computer science at MIT.

Reserve Your Spot

First Name*

Last Name*

Email Address*

Country / Region*

What industry do you work in?*

Organization / Company

Are you a current BioPharmCatalyst subscriber?*

Yes

Are you interested in prospecting, investing, or both?*